Literature DB >> 25610729

Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence.

Laura A Johnson1, Luis Sanchez-Perez2, Carter M Suryadevara2, John H Sampson2.   

Abstract

CAR therapy has shown promise in treating cancer, but at the cost of unexpected toxicity against normal tissues, not predicted by preclinical testing. We are working to generate more physiologically relevant models for preclinical CAR toxicity testing, and in doing so, have discovered that CAR therapy induces immunogenic cell death, with the potential for cures.

Entities:  

Keywords:  adoptive cell therapy; cancer immunology; chimeric antigen receptor; gene-engineering; glioblastoma; tumor immunotherapy

Year:  2014        PMID： 25610729      PMCID： PMC4292711          DOI： 10.4161/21624011.2014.944059

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

Review 2.  Antibody-modified T cells: CARs take the front seat for hematologic malignancies.

Authors:  Marcela V Maus; Stephan A Grupp; David L Porter; Carl H June
Journal:  Blood       Date:  2014-02-27       Impact factor: 22.113

3.  EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.

Authors:  John H Sampson; Bryan D Choi; Luis Sanchez-Perez; Carter M Suryadevara; David J Snyder; Catherine T Flores; Robert J Schmittling; Smita K Nair; Elizabeth A Reap; Pamela K Norberg; James E Herndon; Chien-Tsun Kuan; Richard A Morgan; Steven A Rosenberg; Laura A Johnson
Journal:  Clin Cancer Res       Date:  2013-12-18       Impact factor: 12.531

Review 4.  Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.

Authors:  Vidyalakshmi Chandramohan; Duane A Mitchell; Laura A Johnson; John H Sampson; Darell D Bigner
Journal:  Future Oncol       Date:  2013-07       Impact factor: 3.404

5.  Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.

Authors:  Richard A Morgan; Laura A Johnson; Jeremy L Davis; Zhili Zheng; Kevin D Woolard; Elizabeth A Reap; Steven A Feldman; Nachimuthu Chinnasamy; Chien-Tsun Kuan; Hua Song; Wei Zhang; Howard A Fine; Steven A Rosenberg
Journal:  Hum Gene Ther       Date:  2012-09-24       Impact factor: 5.695

6.  Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor.

Authors:  Shari A Pilon; Carmen Kelly; Wei-Zen Wei
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

Review 7.  Immunogenic cell death in cancer therapy.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Oliver Kepp; Laurence Zitvogel
Journal:  Annu Rev Immunol       Date:  2012-11-12       Impact factor: 28.527

Review 8.  Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.

Authors:  Michael Kalos; Carl H June
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

Review 9.  EGFRvIII-targeted vaccination therapy of malignant glioma.

Authors:  Bryan D Choi; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Roger E McLendon; Darell D Bigner; John H Sampson
Journal:  Brain Pathol       Date:  2009-10       Impact factor: 6.508

10.  EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.

Authors:  Hongsheng Miao; Bryan D Choi; Carter M Suryadevara; Luis Sanchez-Perez; Shicheng Yang; Gabriel De Leon; Elias J Sayour; Roger McLendon; James E Herndon; Patrick Healy; Gary E Archer; Darell D Bigner; Laura A Johnson; John H Sampson
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240
  10 in total
  4 in total

Review 1.  Brain immunology and immunotherapy in brain tumours.

Authors:  John H Sampson; Michael D Gunn; Peter E Fecci; David M Ashley
Journal:  Nat Rev Cancer       Date:  2019-12-05       Impact factor: 60.716

2.  Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice.

Authors:  Ancy Thomas; Saurav Sumughan; Emilia R Dellacecca; Rohan S Shivde; Nicola Lancki; Zhussipbek Mukhatayev; Cristina C Vaca; Fei Han; Levi Barse; Steven W Henning; Jesus Zamora-Pineda; Suhail Akhtar; Nikhilesh Gupta; Jasmine O Zahid; Stephanie R Zack; Prathyaya Ramesh; Dinesh Jaishankar; Agnes Sy Lo; Joel Moss; Maria M Picken; Thomas N Darling; Denise M Scholtens; Daniel F Dilling; Richard P Junghans; I Caroline Le Poole
Journal:  JCI Insight       Date:  2021-11-22

Review 3.  CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies.

Authors:  Hannah M Knochelmann; Aubrey S Smith; Connor J Dwyer; Megan M Wyatt; Shikhar Mehrotra; Chrystal M Paulos
Journal:  Front Immunol       Date:  2018-07-27       Impact factor: 7.561

Review 4.  Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade.

Authors:  Mie Linder Hübbe; Ditte Elisabeth Jæhger; Thomas Lars Andresen; Mads Hald Andersen
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.